Bayer Plc
Industry / private company
Location:
Newbury,
United Kingdom (GB)
ISNI: -
ROR: https://ror.org/05emrqw14
Show on Map:
Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE) (2022)
Green JB, Mottl AK, Bakris G, Heerspink HJL, Mann JFE, Mcgill JB, Nangaku M, et al.
Journal article
Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis (2019)
Becker M, Graf N, Sauter R, Allanore Y, Curram J, Denton CP, Khanna D, et al.
Journal article
Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort (2019)
Wu W, Jordan S, Graf N, Pena JDO, Curram J, Allanore Y, Matucci-Cerinic M, et al.
Journal article
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial (2015)
Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, et al.
Journal article